ClinicalTrials.Veeva

Menu

Anti-neutrophil Cytoplasmic Antibody in Interstitial Lung Disease.

Chinese Academy of Medical Sciences & Peking Union Medical College logo

Chinese Academy of Medical Sciences & Peking Union Medical College

Status

Completed

Conditions

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interstitial Lung Disease

Study type

Observational

Funder types

Other

Identifiers

NCT04413149
PUMCH-ANCA-positive ILD

Details and patient eligibility

About

The purpose of this study is to investigate the clinical features and long-term outcome of anti-neutrophil cytoplasmic antibody (ANCA)-positive interstitial lung disease (ILD) and assess the difference between microscopic polyangiitis (MPA) associated ILD and isolated ANCA-positive idiopathic interstitial pneumonia.

Full description

ILD patients with serum ANCA-positivity were enrolled in this study.

  1. Baseline data collection:

    1. Demographics information (age, gender)
    2. Clinical course
    3. Clinical symptoms and signs (cough, dyspnea, fever, fatigue, crackling, clubbing fingers, mechanics hand)
    4. Laboratory findings (blood and urine routine, liver and renal function tests, erythrocyte sedimentation rate, C reactive protein)
    5. Serologic tests (ANA , Rheumatoid factor , Anti-cyclic citrullinated peptide (CCP), Anti-dsDNA, Anti-Ro (SS-A), Anti-La (SS-B), Anti-Smith, Anti-Scl-70, Anti-Jo-1)
    6. Systemic manifestation if diagnosed as systemic vasculitis
    7. Pulmonary function tests (ventilation and diffusion capacity test)
    8. Chest high-resolution computed tomography (HRCT)
  2. Treatment: treatment will be given according to the experience of each pulmonologist.

  3. Follow-up:

    1. Patients were followed up at least once a year and basic laboratory tests, serologic autoantibodies, pulmonary function test and chest HRCT were evaluated routinely
    2. Follow-up end point was April 2019.
  4. Outcome

Enrollment

80 patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Males and females
  • Aged from 18 to 85 years with informed consent
  • Have a diagnosis of ILD based on clinical symptoms and radiologic features, with or without histopathologic results
  • Have available ANCA testing results during the first visit and follow-up period

Exclusion criteria

  • Connective tissue disease associated ILD
  • ILD induced by drug, environment, or occupational exposure
  • Hypersensitivity pneumonitis and sarcoidosis

Trial design

Trial documents
1

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems